About C-X-C chemokine receptor type 1
C-X-C chemokine receptor type 1 (CXCR1) is a protein
from Homo sapiens identified by UniProt accession
P25024, 350 residues long.
MolForge cross-references it against 0 known binders and
604 disease associations.
Target properties
| Protein name | C-X-C chemokine receptor type 1 |
| UniProt accession | P25024 |
| Gene | CXCR1 |
| Organism | Homo sapiens |
| Length | 350 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (604)
Diseases linked to this target (Open Targets).
- type 1 diabetes mellitus · score 0.35
- neutrophil count · score 0.32
- leukocyte count · score 0.30
- neutrophil percentage of leukocytes · score 0.30
- monocyte percentage of leukocytes · score 0.30
- lymphocyte percentage of leukocytes · score 0.28
- pneumonia · score 0.28
- myeloid white cell count · score 0.28
- glioblastoma multiforme · score 0.28
- COVID-19 · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P25024-F1 | alphafold | PREDICTED | 78.07 | — |
Amino-acid sequence (350 residues)
MSNITDPQMW DFDDLNFTGM PPADEDYSPC MLETETLNKY VVIIAYALVF LLSLLGNSLV MLVILYSRVG RSVTDVYLLN LALADLLFAL TLPIWAASKV NGWIFGTFLC KVVSLLKEVN FYSGILLLAC ISVDRYLAIV HATRTLTQKR HLVKFVCLGC WGLSMNLSLP FFLFRQAYHP NNSSPVCYEV LGNDTAKWRM VLRILPHTFG FIVPLFVMLF CYGFTLRTLF KAHMGQKHRA MRVIFAVVLI FLLCWLPYNL VLLADTLMRT QVIQESCERR NNIGRALDAT EILGFLHSCL NPIIYAFIGQ NFRHGFLKIL AMHGLVSKEF LARHRVTSYT SSSVNVSSNL
Explore C-X-C chemokine receptor type 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets